GENITOURINARY CANCERS

During a Targeted Oncology™ Case-Based Roundtable™ event, Pedro C. Barata, MD, MSc, discussed data supporting the use of sacituzumab govitecan in advanced urothelial carcinoma.

Expert perspectives on the current treatment paradigm for patients diagnosed with locally advanced or metastatic urothelial carcinoma.

In the KEYNOTE-045 and KEYNOTE-052 trials, pembrolizumab continued to led to durable responses with no new safety signals after 5 years.

In an interview with Targeted Oncology™, Rohan Garje, MD, discussed available therapies, how to assess risks, and manage toxicities for patients with renal cell carcinoma.

The phase 1 study of ADXS-504 for the treatment of early prostate cancer is ongoing and new patients with be enrolled to test a higher dose level.

Guru P. Sonpavde, MD, provides rationale for the phase 3b STRONG study, and discusses the early data.

Results from a phase 3 study show that the continuous maintenance therapy of enzalutamide reduces the risk of disease progression in certain patients with metastatic castration resistant prostate cancer.

In a first-in-human trial, a peptide-drug conjugate showed tolerability and antitumor activity in patients with advanced solid tumors.

Patients with metastatic castration-resistant prostate cancer treated with darolutamide for more than 4 years tolerated well the adverse effects of the drug.

The FDA has granted approval to the agent formerly known as 177Lu-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post-taxane-based chemotherapy setting.

In an interview with Targeted Oncology™, Sumtha K. Pal, discussed the most interesting research presented during ASCO Genitourinary Cancers Symposium.

Following the important information provided by the phase 3 VESPER trial, Jean Hoffman-Censits, Md said there are several noteworthy ongoing phase 3 neoadjuvant immunotherapy studies in bladder cancer.

Tracy L. Rose, MD, MPH, discusses ongoing research in bladder cancer that aims to add onto the standard of care and improve patient outcomes.

Overall survival was prolonged with the addition of darolutamide to androgen-deprivation therapy and docetaxel in patient with metastatic, hormone-sensitive prostate cancer.

The phase 2 PERICLES trial of atezolizumab with or without radiotherapy in patients with stage IV cancer did not meet its primary end point of 1-year progression-free survival.

NeoAvAx trial results show that neoadjuvant avelumab/axitinib may be beneficial to patients with renal cell carcinoma.

Health-related quality of life outcomes was more sustainable in patients with advanced renal cell carcinoma on nivolumab plus cabozantinib compared to sunitinib.

A 3-year analysis of updated data from the phase 3 CheckMAte 9ER trial shows the better health-related quality of life outcomes for patients with advanced renal cell carcinoma on nivolumab plus cabozantinib.

Three immune cell-related factors appear to impact response or lack of response to treatment with nivolumab plus ipilimumab in patients with advanced or metastatic renal cell carcinoma.

Tanya Dorff, MD, discusses the current treatment modalities for prostate cancer and the hope that chimeric antigen receptor T cells will improve outcomes.

Mixed results were reported from the phase 2 ARIES clinical trial at the 2022 ASCO GU meeting.

Patients with urothelial cancer whose tumors overexpress c-Met may benefit from this unique combination.

Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT and percent change in lesion number may be associated with overall survival in patients with metastatic genitourinary malignancies.

An exploratory analysis of the phase 3 JAVELIN Bladder 100 trial shows that the overall survival benefit of frontline maintenance avelumab is sustained in patients with advanced urothelial cancer.

Results from the combination of lenvatinib and pembrolizumab show similarity with the comparator in the phase 3 LEAP-011 study.